Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to speed blood recovery in cancer transplants

NCT ID NCT07362810

Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding IL-11 to the standard drug G-CSF helps blood cells recover faster after a stem cell transplant in people with multiple myeloma or lymphoma. About 224 adults will receive either the combination or G-CSF alone before their transplant. The goal is to see if the combo shortens the time for white blood cells and platelets to return to safe levels, reducing the need for transfusions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
G-CSF and IL-11 (drugs to stimulate blood cell production)
What this could lead to
If successful, this combination could speed up recovery of platelets and red blood cells after transplant, reducing the need for transfusions.
What could go wrong
This is a mid-stage trial with 224 participants, so results are not yet proven. The added drug may cause side effects or not improve outcomes significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 224 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years) with newly diagnosed multiple myeloma or lymphoma * Suitable candidates for autologous hematopoietic stem cell transplantation (auto-HSCT) * Zubrod (ECOG) performance status \< 4 * Left ventricular ejection fraction (LVEF) \> 40% * No uncontrolled arrhythmia or unstable cardiac disease * Corrected QT interval (QTc) \< 470 ms * No symptomatic pulmonary disease, with acceptable pulmonary function tests * Serum alanine aminotransferase (ALT) \< 4 × upper limit of normal (ULN) * Total bilirubin \< 2 × upper limit of normal (ULN) Exclusion Criteria: * Intolerance to auto-HSCT * Prior exposure to other stem cell mobilizing agents * Pregnancy or lactation * Psychiatric disorders precluding participation * Positive serology for HIV (HIV-1/2), hepatitis B, or hepatitis C

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemato-oncologic patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemato-oncologic patients Hematopoetic stem cell transplantation Mobilization of hematopoietic stem cells (HSC) to peripheral blood (PB)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Huadong Hospital, Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200040, China

  • The first affiliated hospital of Zhengzhou university

    RECRUITING

    Zhengzhou, Henan, 450052, China

  • Tongji Hospital of Tongji University

    RECRUITING

    Shanghai, Shanghai Municipality, 200065, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.